By combining the two newly discovered genetic variants with non-genetic factors like age, sex, and medical history (such as type 2 diabetes status), individuals can receive personalized estimates for their likelihood of weight loss and side effects
In 1981, for example, a paper published in the International Journal of Clinical Pharmacology, Therapy, and Toxicology described a trial with six volunteers who experienced immediate sleep pressure after intravenous DSIP infusion, as well as increased sleep time, decreased sleep onset, and better sleep efficiency without any sedative effects.13 Three years later, two other human trials across ten test subjects with insomnia found that DSIP administration yielded statistically significant improvements in several key sleep measures fewer sleep arousals, greater sleep efficiency, and increased REM, spindle, and slow-wave sleep.14 The above studies had shortcomings, namely their very small sample sizes, but the sleep-improving effects in cases of insomnia point to DSIPs potential to live up to its name
Switching between them Moving between GLP-1 treatments is common and is done regularly, but there is no official published dose-equivalence table for weight management
This article provides an in-depth assessment of the effectiveness of GLP1RAs across multiple body systems while delving into potential signaling pathways and pharmacological mechanisms
These pharmacokinetic differences inform the trade-offs in onset, convenience, and dosing convenience
